Dietary effects on drug metabolism and transport

被引:160
作者
Harris, RZ
Jang, GR
Tsunoda, S
机构
[1] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
[2] Univ Calif San Francisco, Gen Clin Res Ctr, San Francisco, CA 94143 USA
关键词
D O I
10.2165/00003088-200342130-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metabolic food-drug interactions occur when the consumption of a particular food modulates the activity of a drug-metabolising enzyme system, resulting in an alteration of the pharmacokinetics of drugs metabolised by that system. A number of these interactions have been reported. Foods that contain complex mixtures of phytochemicals, such as fruits, vegetables, herbs, spices and teas, have the greatest potential to induce or inhibit the activity of drug-metabolising enzymes, although dietary macroconstituents (i.e. total protein, fat and carbohydrate ratios, and total energy intake) can also have effects. Particularly large interactions may result from the consumption of herbal dietary supplements. Cytochrome P450 (CYP) 3A4 appears to be especially sensitive to dietary effects, as demonstrated by reports of potentially clinically important interactions involving orally administered drugs that are substrates of this enzyme. For example, interactions of grapefruit juice with cyclosporin and felodipine, St John's wort with cyclosporin and indinavir, and red wine with cyclosporin, have the potential to require dosage adjustment to maintain drug concentrations within their therapeutic windows. The susceptibility of CYP3A4 to modulation by food constituents may be related to its high level of expression in the intestine, as well as its broad substrate specificity. Reported ethnic differences in the activity of this enzyme may be partly due to dietary factors. Food-drug interactions involving CYP1A2, CYP2E1, glucuronosyltransferases and glutathione S-transferases have also been documented, although most of these interactions are modest in magnitude and clinically relevant only for drugs that have a narrow therapeutic range. Recently, interactions involving drug transporters, including P-glycoprotein and the organic anion transporting polypeptide, have also been identified. Further research is needed to determine the scope, magnitude and clinical importance of food effects on drug metabolism and transport.
引用
收藏
页码:1071 / 1088
页数:18
相关论文
共 175 条
[11]   VERAPAMIL INHIBITS ETHANOL ELIMINATION AND PROLONGS THE PERCEPTION OF INTOXICATION [J].
BAUER, LA ;
SCHUMOCK, G ;
HORN, J ;
OPHEIM, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) :6-10
[12]   Effect of grapefruit juice on digoxin pharmacokinetics in humans [J].
Becquemont, L ;
Verstuyft, C ;
Kerb, R ;
Brinkmann, U ;
Lebot, M ;
Jaillon, P ;
Funck-Brentano, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) :311-316
[13]   The drug efflux-metabolism alliance: biochemical aspects [J].
Benet, LZ ;
Cummins, CL .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 50 :S3-S11
[14]   Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram [J].
Benton, RE ;
Honig, PK ;
Zamani, K ;
Cantilena, LR ;
Woosley, RL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (04) :383-388
[15]   Paracetamol (acetaminophen)-induced toxicity: Molecular and biochemical mechanisms, analogues and protective approaches [J].
Bessems, JGM ;
Vermeulen, NPE .
CRITICAL REVIEWS IN TOXICOLOGY, 2001, 31 (01) :55-138
[16]   Effect of grapefruit juice on Sandimmun Neoral® absorption among stable renal allograft recipients [J].
Bistrup, C ;
Nielsen, FT ;
Jeppesen, UE ;
Dieperink, H .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (02) :373-377
[17]   CONSUMPTION OF BRUSSELS-SPROUTS RESULTS IN ELEVATED ALPHA-CLASS GLUTATHIONE-S-TRANSFERASE LEVELS IN HUMAN BLOOD-PLASMA [J].
BOGAARDS, JJP ;
VERHAGEN, H ;
WILLEMS, MI ;
VANPOPPEL, G ;
VANBLADEREN, PJ .
CARCINOGENESIS, 1994, 15 (05) :1073-1075
[18]   Modulation of cytochrome P-450 and glutathione S-transferase isoform expression in vivo by intact and degraded indolyl glucosinolates [J].
Bonnesen, C ;
Stephensen, PU ;
Andersen, O ;
Sorensen, H ;
Vang, O .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1999, 33 (02) :178-187
[19]  
BOOBIS AR, 1994, CANCER RES, V54, P89
[20]   Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion [J].
Boyd, RA ;
Stern, RH ;
Stewart, BH ;
Wu, XC ;
Reyner, EL ;
Zegarac, EA ;
Randinitis, EJ ;
Whitfield, L .
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (01) :91-98